Shares of Nektar Therapeutics (NASDAQ:NKTR) added ~9% in the premarket on Friday after Oppenheimer upgraded the biopharma to Outperform from Perform, citing a favorable valuation setup ahead of a ...

Nektar Therapeutics NKTR incurred an adjusted loss per share of 15 cents in the fourth quarter of 2024, wider than the Zacks Consensus Estimate of a loss of 13 cents. In the year-ago quarter, the ...

Cash Runway: Expected to extend into Q4 2026. Nektar Therapeutics (NASDAQ:NKTR) completed enrollment for its Phase IIB studies in atopic dermatitis and alopecia areata on schedule, demonstrating ...

Nektar Therapeutics (NKTR) came out with quarterly earnings of $0.15 per share, beating the Zacks Consensus Estimate of a loss of $0.13 per share. This compares to loss of $0.22 per share a year ago.

Lilly partnered with Nektar on the drug in 2017, paying $150 million upfront with another $250 million at the back end in development and regulatory milestones. It has agreed to fund 75% of the ...

With Takeda’s £46 billion acquisition of Shire, it’s been a busy year for pharma M&A – and according to analysts Datamonitor, the specialist biotechs Nektar, BioMarin and Alnylam are the ...